Frangula bark 100mg / Taraxacum 100mg tablets
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Browse all Drug Analysis Profiles A–Z
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
Search EudraVigilance database
Browse substances A–Z in the European adverse reaction database
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
1 branded products available
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF code shown is the factual mapping value distributed by NHS Business Services Authority (NHSBSA) in the dm+d supplementary file under OGL v3.0; it is not affiliated with, nor licensed from, the publishers of the British National Formulary.
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
Reviews & meta-analyses: 1 · 1981–2026
Showing the 50 most relevant studies, sorted by most relevant.
Jan Kirschner, Jan Štěpánek
TAXON, 2011
Olim K. Khojimatov, Dilovar T. Khamraeva, Rainer W. Bussmann
Ethnobiology, 2023
Alexander N. Sennikov
Botanica, 2024
The botanical publications of Boris S. Kharitontsev, who has worked on the flora and vegetation of Tobolsk District (Tyumen Region, south-western Siberia, Russia) for 30 years, make a typical case of grey literature in taxonomic botany. Kharitontsev has described about 400 local “new species” from a single district in this floristically poor territory. Although the taxonomic results of this work are not credible, this vast nomenclatural output requires attention and urges for comprehensive indexing due to requirements of the botanical nomenclature (principles of priority and homonymy). A new species name, Taraxacum stepanekii Sennikov, is proposed for Taraxacum roseolum Kirschner & Štěpánek from Kyrgyzstan, which is an illegitimate later homonym of Taraxacum roseolum Charit.
Abstract licence: CC BY
Michael J. Zwerger, Anna Deisl, Fabian Hammerle, et al.
Journal of chromatography. A, 2024
Liis Luhamaa, Riina Rammo, Debbie Bamford, et al.
Heritage, 2025
This article sheds light on the historical dyeing traditions of rural inhabitants of the Eastern Baltic region. The 19th- and early 20th-century Estonian archival sources mention that rotted alder buckthorn (Frangula alnus Mill.) bark was used to dye woollen yarn red. The bark was rotted by leaving it outside for weeks or months before dyeing. Although dyeing red with alder buckthorn bark by fermenting it in wood ash lye is well known, the combination of rotting the bark and using the boiling method to dye red has not been reported. Practical experiments testing shorter and longer-term rotting of alder buckthorn bark both on and under the ground were conducted. Woollen yarns were dyed with rotted bark using the boiling method and were tested for lightfastness and alkaline pH sensitivity, and analysed using HPLC-DAD. The results show that rotting alder buckthorn bark has a strong effect on the achievable colours and that woollen yarns can be dyed different shades of red. The colours were sensitive to alkaline pH and their light fastness varied from very low to good. HPLC-DAD analysis showed that the pretreatment of the bark affected not only the colour but also the dye composition of the dyed wool.
Abstract licence: CC BY
P. G. Efimov
Novitates Systematicae Plantarum Vascularium, 2023
Ingo Uhlemann, Steffen Hammel, Klaus Jung, et al.
Kochia, 2025
Petr G. Efimov, Ekaterina O. Golovina
Turczaninowia, 2025
Özlem Kara, Asuman Kilitçi
Journal of Surgery and Medicine, 2023
Background/Aim: The use of doxorubicin is limited due to its toxic effects on normal cells. A substance containing antioxidant properties, such as taraxacum officinale, would be useful in preventing doxorubicin toxicity. This study aimed to evaluate the effect of taraxacum officinale on doxorubicin-induced damage in the rat liver. Methods: Forty Wistar albino rats were allocated into four groups. In group 1 (control group), no treatment was given. In group 2 (Taraxacum officinale, group T), 100 mg/kg Taraxacum officinale was administered via the gavage route for 10 days. In group 3 (doxorubicin, group D), a single intraperitoneal dose of 40 mg/kg doxorubicin was given. In group 4 (doxorubicin + Taraxacum officinale, group D+T), a single intraperitoneal dose of 40 mg/kg doxorubicin was administered on the eighth day, and 100 mg/kg Taraxacum officinale was administered for 10 days. Blood malondialdehyde (MDA) levels and the activities of catalase (CAT) and superoxide dismutase (SOD) were measured. Histopathology was assessed by examining preparations of hepatic tissue with light microscopy and immunohistochemistry. Results: MDA levels were significantly higher, and the activities of SOD and CAT were lower in group D than in group D+T (P=0.04). Tissue damage was significantly higher in group D than in group D+T (P=0.03). Conclusion: Our short-term results indicate that oxidative stress could be responsible for the damage to liver tissue due to doxorubicin, and Taraxacum officinale might reverse these harmful effects.
Abstract licence: CC BY-NC-ND 4.0
Liis Luhamaa, Riina Rammo, Debbie Bamford
Studia Vernacula, 2024
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Scientific data (pharmacology, interactions, ADME) is not yet available for this medicine. Clinical sections are sourced from the NHS dm+d database.